Skip to content

Treating Type 2 Diabetes by Reducing Postprandial Glucose Elevations: A Paradigm Shift in Lifestyle Modification

Treating Type 2 Diabetes by Reducing Postprandial Glucose Elevations: A Paradigm Shift in Lifestyle Modification

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03196895
Enrollment
192
Registered
2017-06-23
Start date
2017-06-28
Completion date
2020-10-05
Last updated
2021-10-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Type 2

Keywords

Diabetes Mellitus, Type 2, Continuous Glucose Monitoring, Lifestyle Modification

Brief summary

Conventional lifestyle modification in the management of type 2 diabetes focuses on weight loss, through caloric restriction and exercise, to reduce insulin resistance. This approach is limited because some people either do not need to lose weight, do not want to lose weight, cannot lose weight, or cannot maintain weight loss over a lifetime. This study proposes to evaluate the effectiveness of a lifestyle modification that focuses on reducing post-meal blood glucose (BG) elevations instead of weight loss. It works by teaching participants to: 1) choose low glycemic load foods that do not significantly increase their blood glucose, and 2) increase their routine physical activity after meals when it can offset post-meal blood glucose elevations. The study will also evaluate the role feedback about blood glucose fluctuations can play in improving the effectiveness of this program.

Detailed description

BACKGROUND: Type 2 diabetes (T2D) is a growing epidemic in the U.S. with devastating complications that result in major health and personal costs. To address this, the American Diabetes Association recommends a lifestyle program that focuses on weight loss through caloric restriction and exercise as an initial or an adjunct treatment to pharmacological interventions. However, its general applicability is limited because some individuals with T2D do not need to lose weight, do not want to lose weight, cannot lose weight, or cannot maintain weight loss over a lifetime. Recent research indicates that a major contributor to poor metabolic control is postprandial glucose (PPG) elevation. The researchers have developed a treatment option that focuses on reducing PPG without requiring weight loss. This lifestyle program is comprehensive, integrated, and efficient. Over 5 sessions, this program empowers individuals to use Glycemic load of food, Exercise, and Monitoring glucose (GEM) in a systematic manner. GEM's 1.03% HbA1c reduction compared favorably to both conventional weight loss (0.64% reduction with 42 sessions of Look AHEAD) and continual use of a first line medication (0.9% reduction with Metformin). When enhancing the quantity and quality of glucose feedback with Continuous Glucose Monitoring (CGM), GEM reduced HbA1c by 1.30%. AIMS: This project will determine how GEM compares to conventional weight reduction at short- and long-term follow-up in a large, representative sample of adults with type 2 diabetes. At the same time, the researchers will test a conceptual model based on a review of the literature postulating that the effects of GEM are modulated by the quality and quantity of glucose feedback. This has important implications for long-term maintenance; since the model proposes a cascade in which increasing either the quantity or quality of glucose feedback improves immediate behavior change through positive and negative glucose consequences. These contingencies may lead to improved PPG and insulin sensitivity, and in turn, improved metabolic control. This cascade may produce ancillary benefits that could help maintain long-term success, e.g. greater empowerment and fewer depressive symptoms. APPROACH: 200 participants with poorly controlled T2D will be randomized to 1 of 4 groups that manipulate both the focus on postprandial glucose and the quality and quantity of glucose feedback. Short- and long-term benefits will be assessed using medical, behavioral and psychological measures obtained at baseline, 3 months post-intervention and 12 months post-intervention. IMPACT: If GEM is shown to be effective and enduring, it will provide an alternative to the conventional weight-loss focused lifestyle modification. GEM has the potential to improve metabolic control, increase self-reliance, and slow disease progression. Because GEM is manual-based, it will be easy to deploy and will give it the potential to impact a large proportion of the adults with T2D.

Interventions

BEHAVIORALWeight reduction training

6 one-hour sessions of conventional weight reduction training

BEHAVIORALPPG training

Four 90-minute sessions of glycemic load and exercise training

BEHAVIORALdiscrete BG feedback

Blood glucose feedback from structured self-monitoring of blood glucose

BEHAVIORALcontinuous BG feedback

blood glucose feedback from continuous glucose monitoring

Sponsors

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
CollaboratorNIH
University of Virginia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
21 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosed with T2D in the last 10 years * HbA1c \>7.5% (sub-optimal T2D control) * Between 21 and 80 years old * Not blind * Can read English * Routinely uses a smart phone

Exclusion criteria

* Takes insulin (participants may start insulin during the study if clinically indicated) * Has taken medications that impede weight loss (e.g., prednisone) within the last 3 months * Currently pregnant or contemplating pregnancy within the next 15 months * Conditions that preclude increasing physical activity (e.g. severe neuropathy cardiovascular disease, chronic obstructive pulmonary disease/emphysema, osteoarthritis, stroke, or severe mental disease like manic depressive illness, severe depression, active substance abuse) * Undergoing treatment for cancer * History of lactic acidosis * Marked renal impairment (eGFR \< 45; stage 3b chronic kidney disease) * Takes psychotropic medications that raise blood glucose (e.g. atypical antipsychotics) * Cannot read English * Blindness * Cognitive impairment

Design outcomes

Primary

MeasureTime frameDescription
change in HbA1cbaseline, 3 months, and 12 months post-interventionchange in HbA1c from baseline measure
change in medicationbaseline, 3 months, and 12 months post-interventionchange in medication type or dose from baseline measures

Secondary

MeasureTime frameDescription
change in physical activity (Fitbit activity monitor)baseline, 3 months, and 12 months post-interventiondaily activity will be recorded
change in psychological functioning (dietary habits questionnaire)baseline, 3 months, and 12 months post-interventionThe Food Questionnaire
change in psychological functioning (quality of life questionnaire)baseline, 3 months, and 12 months post-interventionWHOQO-BREF questionnaire
change in psychological functioning (depression questionnaire)baseline, 3 months, and 12 months post-interventionPatient Health Questionnaire (PHQ-9)
change in food choices (ASA24 survey)baseline, 3 months, and 12 months post-interventionASA24 survey across 3 separate days in each time frame
change in psychological functioning (diabetes knowledge questionnaire)baseline, 3 months, and 12 months post-interventionDiabetes Knowledge Scale
change in psychological functioning (empowerment questionnaire)baseline, 3 months, and 12 months post-interventionDiabetes Empowerment Scale
change in psychological functioning (concerns about diabetes questionnaire)baseline, 3 months, and 12 months post-interventionDiabetes Distress Scale (Emotional Distress & Regimen Distress subscales)
change in psychological functioning (attitude towards glucose monitoring questionnaire)baseline, 3 months, and 12 months post-interventionThe Glucose Monitoring Satisfaction Survey (GMSS)
change in psychological functioning (numeracy questionnaire)baseline, 3 months, and 12 months post-interventionNumeracy Scale - measures how good one is with numbers
change in food choices (energy bar selection)baseline, 3 months, and 12 months post-interventionAt assessment visits, subjects will choose between energy bars that do or dont support the intervention principles.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 17, 2026